Neurocrine Biosciences, Inc.
Neurocrine Biosciences is a biopharmaceutical company founded in 1992, specializing in treatments for neurological, neuroendocrine, and neuropsychiatric disorders. The company has successfully commercialized key therapies like INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease, and CRENESSITY for classic congenital adrenal hyperplasia. In 2026, it significantly expanded its portfolio by acquiring Soleno Therapeutics, adding VYKAT XR for Prader-Willi syndrome, further solidifying its position in rare diseases.